{"id":984793,"date":"2026-07-27T06:03:27","date_gmt":"2026-07-27T10:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/"},"modified":"2026-07-27T06:03:27","modified_gmt":"2026-07-27T10:03:27","slug":"legend-biotech-announces-ceo-transition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/","title":{"rendered":"Legend Biotech Announces CEO Transition"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <em>Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition<\/em>\n        <\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <em>Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer<\/em>\n        <\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <em>Board has initiated a comprehensive search process to identify a permanent successor<\/em>\n        <\/li>\n<\/ul>\n<p>BRIDGEWATER, N.J., July  27, 2026  (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (\u201cLegend Biotech\u201d or the \u201cCompany\u201d), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition.<\/p>\n<p>The Board has appointed Alan Bash, current President of the CARVYKTI Business Unit, as Interim Chief Executive Officer. The Board has also initiated a comprehensive search process to identify a permanent successor.<\/p>\n<p>\u201cOn behalf of the Board, I want to thank Ying for his leadership, dedication and many contributions to Legend Biotech during the past seven years,\u201d said Frank Zhang, EMBA, Ph.D., Chairman of the Board of Legend Biotech. \u201cDuring his tenure, Legend Biotech advanced from a pioneering cell therapy company into a global leader with a strong commercial foundation, a differentiated innovation platform, and a clear commitment to patients. We are grateful for Ying\u2019s continued support through the transition and wish him well in his next chapter.\u201d<\/p>\n<p>Dr. Zhang continued, \u201cThe Board has full confidence in Alan\u2019s ability to provide continuity and disciplined execution during this period. Alan has deep knowledge of our business, significant commercial and operational experience, and a strong understanding of the opportunity ahead. We remain focused on advancing our priorities, supporting continued growth, and ensuring Legend Biotech is well positioned to deliver on its mission for patients.\u201d<\/p>\n<p>\u201cIt has been a privilege to lead Legend Biotech and to work alongside such a talented and committed team,\u201d said Dr. Huang. \u201cI am deeply grateful to my colleagues, the Board and our partners for their dedication, resilience and shared commitment to patients. Together, we have helped advance cell therapy in meaningful ways and built a strong foundation for the company\u2019s future. I remain highly confident in the Company\u2019s strategy, pipeline and long-term growth opportunities. Our priorities are clear, our strategy is unchanged, and we are focused on execution. I look forward to supporting a smooth transition and watching Legend Biotech continue to make an important impact for patients and families.\u201d<\/p>\n<p>\u201cI am honored to step into the role of Interim CEO and grateful for the Board\u2019s confidence,\u201d said Mr. Bash. \u201cLegend Biotech has a clear mission, a strong team and important opportunities ahead. My immediate focus will be on ensuring continuity across the business, maintaining strong execution, and supporting our teams as we continue advancing our commercial, clinical, and operational priorities. We remain committed to bringing innovative cell therapies to more patients around the world.\u201d<\/p>\n<p align=\"justify\">\n        <strong>ABOUT\u00a0LEGEND BIOTECH<\/strong><br \/>\n        <br \/>With over 3,000 employees,\u00a0Legend Biotech\u00a0is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever.\u00a0Legend Biotech\u00a0is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>\u00ae<\/sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in\u00a0the United States,\u00a0Legend Biotech\u00a0is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI\u2019s patient access and therapeutic potential. From this platform,\u00a0Legend Biotech\u00a0plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.<\/p>\n<p align=\"justify\">Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fx-2W969uTSua1dOUnBDmtj4GwvE7s0fkz7daEsmX0UUOLT_mf9w97DccClttERmXKntbNNOmXTMRARYYZ8Uann2PsUAaJJ41XgsiJq1B-UBv0bYmJ8RYoFqKX3A0JlIlTSUvmycx4vdQbYXOavfjwcmgcZvAWgIA7mdOoRWhxaKSgDr4iwWCJDPpchrNRvkBRCkMkMoNKlNkh7fZKTOBtGRnfiKFofNiucD2J06TJxIhUR5jqeuy5LQiQvXTJxaEXmbtDrzpL7coMg6N_GJcA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/legendbiotech.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9ehL5cfj90vJIkV_eQRf378yyPMGq-kI_rUN_4tcWhUVJ8KB4tQLKD5v9cwZDk9XV2NJg7cFq2HlvuGvd5Z-CERq5R-JsG1_T3777lwfYNIVuq7TB0y7obqZn8fBtI6nYVK9SHo2-C7N5XISc1NFanMM4NeJPtOmwd8zUmUQGRL7BxWOeSx1UDPMghWHJZJsUfSDXoqxvuu43FlAv7_NBg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h9nqOjEisAlpXDcaWokitllNvuF0dC9Azdnf_3UjMHQH57BiTwfudUqdZXdKXPhX-3eg4HhqEBusO2mj1LKuj-UJepUKRUBXWdKUf3xqA6MkmEJf_CruBXTq6YMgVMv0LFfc8rPxCTPrEPceyloyzo642Jgh59seGQI7AddfyjIcJVFoILt2StO0YauGS3GVy_r-2cMcupMZCcwHiZQ3V2kaeLJxYOLBeS_Jtq2tzKXxXGWHDo4x-7puAuLTc5CXk4wIn2lnS2O2zDVpzP-R98fzpAvVPsto-MZKWoxTbN8KFwfUMBR1Ug6ytUXSx65A\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <em>Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech\u2019s continued execution and advancement of commercial, clinical and operational priorities, strategy and long-term growth opportunities. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech\u2019s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and\/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech\u2019s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the \u201cRisk Factors\u201d section of Legend Biotech\u2019s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.<\/em>\n      <\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Caroline Paul<br \/>Tel: 973-650-5832<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qdGQO7KI613VHmHWGVdo_3p4Y134ed6e-fExv9JLAjLa1Jeta2yBz-FrU2N9rpm-NkSek64JVRXeLZeHYeoTwyWY2DFzG3BbbZBHrpOj3e81-uvz2UsOAeva3VZ0AlTV\" rel=\"nofollow\" target=\"_blank\">investor@legendbiotech.com<\/a><\/p>\n<p>\n        <strong>PRESS CONTACT:<\/strong><br \/>\n        <br \/>Kim Fox<br \/>Tel: (848) 388-8445<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yq0cuGZZ_ccT3HN2XcUTVLlU0zEVa6gG3pnCmf-k2_fEEoNxxRzuIjasILR3dqdvyIO-VbXBKNweLIl6Vf6S8V0McpTNI0BaA_B3Km0cYpONm4n8FrbZmXGsIRurycyi\" rel=\"nofollow\" target=\"_blank\">media@legendbiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWE0OWUzNWYtOWI3Zi00YzUxLWJjZTYtYmZiN2QwMDc3NzQyLTEyMDY1MDUtMjAyNi0wNy0yNy1lbg==\/tiny\/Legend-Biotech-USA-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer Board has initiated a comprehensive search process to identify a permanent successor BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (\u201cLegend Biotech\u201d or the \u201cCompany\u201d), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Legend Biotech Announces CEO Transition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-984793","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Legend Biotech Announces CEO Transition - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legend Biotech Announces CEO Transition - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer Board has initiated a comprehensive search process to identify a permanent successor BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (\u201cLegend Biotech\u201d or the \u201cCompany\u201d), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition. &hellip; Continue reading &quot;Legend Biotech Announces CEO Transition&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-27T10:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Legend Biotech Announces CEO Transition\",\"datePublished\":\"2026-07-27T10:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/\"},\"wordCount\":975,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/\",\"name\":\"Legend Biotech Announces CEO Transition - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=\",\"datePublished\":\"2026-07-27T10:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-ceo-transition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legend Biotech Announces CEO Transition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Legend Biotech Announces CEO Transition - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/","og_locale":"en_US","og_type":"article","og_title":"Legend Biotech Announces CEO Transition - Market Newsdesk","og_description":"Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer Board has initiated a comprehensive search process to identify a permanent successor BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (\u201cLegend Biotech\u201d or the \u201cCompany\u201d), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition. &hellip; Continue reading \"Legend Biotech Announces CEO Transition\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-27T10:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Legend Biotech Announces CEO Transition","datePublished":"2026-07-27T10:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/"},"wordCount":975,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/","name":"Legend Biotech Announces CEO Transition - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=","datePublished":"2026-07-27T10:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc4ODIyMyM3NzQzNDc4IzIxOTQ5NTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-ceo-transition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Legend Biotech Announces CEO Transition"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=984793"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=984793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=984793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=984793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}